| CPC A61K 9/0021 (2013.01) [A61K 31/658 (2023.05); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61M 2037/0023 (2013.01); A61M 2037/0053 (2013.01)] | 5 Claims |
|
1. A dissolving microneedle, comprising: an excipient and a pharmaceutical ingredient containing a nanosized cannabidiol (CBD) suspension; wherein the dissolving microneedle further comprises a pore-forming agent comprising one or more selected from the group consisting of trehalose, maltose, sucrose and magnesium chloride; and the nanosized CBD suspension comprises: nanosized CBD and a stabilizer, a concentration of the nanosized CBD in the nanosized CBD suspension is in a range of 10 to 100 mg/mL, a particle size of the nanosized CBD is in a range of 50 to 1000 nanometers (nm), and content of the nanosized CBD in the dissolving microneedle is in a range of 1.5 to 25 weight percent (wt %);
wherein the stabilizer comprises one or more selected from the group consisting of poloxamer, polysorbate, polyoxyethylene alkyl ether, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose and carboxymethyl chitosan, and the excipient comprises polyvinyl pyrrolidone, polyvinyl alcohol, sodium carboxymethyl cellulose, hyaluronic acid, or hydroxyethyl cellulose.
|